Nama Insights

Becton, Dickinson (BDX)

Healthcare · Medical Instruments Supplies · NYSE

S&P 500
Becton, Dickinson (BDX) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $57.71B, a trailing price-to-earnings ratio of 16.1 and a free-cash-flow yield of 4.4%. Over the most recent reported fiscal year, revenue grew 8.2% and free cash flow per share fell 12.3%. Nama's AI scorecard rates it Hold, 4.5 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Hold · 4.5/10
The sections balance. As of Nov 7, 2026.
Momentum
Middle · +1.6% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-26.3%
How far the last close sits under the highest price of the past five years.
Market cap$57.71B
Trailing P/E16.1
Price / book2.4
Price / sales2.6
FCF yield4.4%
Dividend yield2.0%
Gross margin46.4%
Operating margin13.8%
Net margin4.5%
Revenue growth (YoY)+8.2%
Revenue growth (3-yr annual)+5.0%
EPS growth (YoY)+9.6%
FCF/share growth (YoY)-12.3%
Beta0.3
ExchangeNYSE
SectorHealthcare
IndustryMedical Instruments Supplies

BDX earnings

Next report: Feb 9, 2027 (Q1 2027, EPS estimate $2.73). Beat the EPS estimate in 4 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q4 2026 Nov 5, 2026 $4.15 $4.07 +2.0% —
Q3 2026 Aug 6, 2026 $3.23 $3.14 +2.9% $4.98B
Q2 2026 May 7, 2026 $2.90 $2.77 +4.7% $4.71B
Q1 2026 Feb 9, 2026 $2.91 $2.81 +3.6% $5.25B

BDX analyst price target

Median target $197.50 from 14 analysts, ranging $165.00 – $225.00.

Medical Instruments Supplies peers

TickerCompanyMarket capP/E
ISRG Intuitive Surgical $159.96B 41.8
MDLN Medline $52.17B 25.1
ALC Alcon $36.23B 23.0
RMD ResMed $33.10B 20.4
WST West Pharmaceutical Services $27.85B 43.5
SOLV Solventum $15.38B 12.8
BAX Baxter International $13.34B 13.3
COO Cooper Companies $11.86B 13.5
Explore live BDX data on Nama Insights →

Recent Congressional trades

Becton, Dickinson trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member Chamber Trade Amount Disclosed
Alan Armstrong Senate Buy $1,001 - $15,000 Jul 21, 2026
Thomas H. Kean House Sell $1,001 - $15,000 Jun 18, 2026
Kevin Hern House Sell $15,001 - $50,000 Apr 3, 2026
Lisa McClain House Sell $1,001 - $15,000 Aug 13, 2025
Lisa McClain House Buy $1,001 - $15,000 Aug 13, 2025
Thomas H. Kean House Buy $1,001 - $15,000 Jun 17, 2025
Rob Bresnahan House Buy $1,001 - $15,000 Jun 9, 2025
Rob Bresnahan House Sell $1,001 - $15,000 Apr 28, 2025
Jefferson Shreve House Sell $15,001 - $50,000 Apr 11, 2025
John James House Sell $1,001 - $15,000 Sep 6, 2024
John James House Buy $1,001 - $15,000 Sep 2, 2024
Thomas H. Kean House Buy $1,001 - $15,000 Jun 18, 2024

BDX FAQ

Is BDX a buy?
Nama's AI scorecard currently rates Becton, Dickinson Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is BDX's P/E ratio?
Becton, Dickinson trades at a trailing price-to-earnings ratio of 16.1.
When does BDX report earnings?
Becton, Dickinson's next scheduled report is on Feb 9, 2027. Analysts expect EPS of $2.73.
What is the BDX price target?
The median analyst price target from 14 analysts is $197.50, with a range of $165.00 – $225.00.
Is BDX Shariah compliant?
Nama's AAOIFI-style screen reads Becton, Dickinson as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does BDX pay a dividend?
Yes — Becton, Dickinson's dividend yield is 2.0%.

See more: Healthcare stocks →